Short Interest in LifeMD, Inc. (NASDAQ:LFMDP) Declines By 40.0%

LifeMD, Inc. (NASDAQ:LFMDP) was the recipient of a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 300 shares, a decrease of 40.0% from the October 31st total of 500 shares. Based on an average trading volume of 1,900 shares, the days-to-cover ratio is presently 0.2 days.

LifeMD Trading Up 1.5 %

Shares of NASDAQ:LFMDP traded up $0.33 during trading hours on Thursday, reaching $22.70. The stock had a trading volume of 649 shares, compared to its average volume of 6,632. LifeMD has a 1 year low of $17.15 and a 1 year high of $25.00. The firm’s 50 day moving average is $22.30 and its 200-day moving average is $22.18.

LifeMD Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, October 15th. Stockholders of record on Friday, October 4th were issued a $0.5547 dividend. This represents a $2.22 annualized dividend and a dividend yield of 9.77%. The ex-dividend date was Friday, October 4th.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.